Status:
COMPLETED
ONO-7913 Phase I Study (ONO-7913)
Lead Sponsor:
Ono Pharmaceutical Co. Ltd
Conditions:
Solid Tumor
Eligibility:
All Genders
20+ years
Phase:
PHASE1
Brief Summary
To assess the tolerability, safety, and pharmacokinetics (PK) of ONO-7913 in patients with advanced or metastatic solid cancers and explore its efficacy and biomarkers.
Eligibility Criteria
Inclusion
- Patients with histologically or cytologically confirmed advanced or metastatic solid tumors
- ECOG Performance Status of 0-1
- Patients with life expectancy of at least 3 months
Exclusion
- Patients with multiple cancers
- Patients with history of serious allergy
Key Trial Info
Start Date :
July 28 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 13 2022
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT04403308
Start Date
July 28 2020
End Date
January 13 2022
Last Update
May 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Chuo-ku, Tokyo, Japan